Recent data has reportedly demonstrated the ability of the Precision Spectra spinal cord stimulator (SCS), marketed by Natick, Mass-based Boston Scientific Corporation, to sustain “highly significant” low back pain relief 6 months following implantation. The retrospective data was presented at the World Institute of Pain (WIP) 7th World Congress in Maastricht, The Netherlands, May 7 to 10.
A news release issued by Boston Scientific notes that its Precision Spectra is engineered to improve pain relief using Illumina 3D Software, a three dimensional anatomy-driven computer model. The software aims to combat a common challenge in SCS therapy, which hinges on stimulating the neural target without stimulating undesired areas. As a result, the release states that the Illumina 3D Software is built for simple point-and-click pain targeting, taking into account the conductivity of 3D anatomical structures and physician placement of the SCS leads.
The retrospective study encompassed a total of 213 patients at 13 centers targeting patients with chronic pain who were treated with the Precision Spectra SCS system. According to the release, to date 140 patients have reached 6 months post-implant. The study’s results indicate a sustained and highly significant reduction in pain from an average baseline score of 7.15, on a 10-point scale, to an average score of 2.93 at 6 months post-implant.
In patients with only low back pain, the results suggest a sustained and highly significant reduction of low back pain, from an average baseline score of 7.53, on a 10-point scale, to an average of 3.45 at 6 months post-implant. The study also indicates in patients with severe low back pain, a sustained and highly significant reduction in pain, from an average score of 8.78 at baseline at 6 months post-implant.
Salim Hayek, MD, PhD, chief, Division of Pain Medicine, University Hospitals of Cleveland, explains that, “In this study, these retrospective results demonstrate that the Precision Spectra System is maintaining effective therapy for these challenging patients out to 6 months post-implant.”
Maulik Nanavaty, president, Neuromodulation, Boston Scientific, echoes Hayek, adding that the 6-month results “demonstrate our dedication to improving the lives of patients with chronic pain through meaningful innovation. We look forward to the long-term outcomes of this ongoing clinical study.”
The release reports that the clinical data presented at WIP are part of a clinical program established to characterize the benefits of the Precision Spectra System in providing pain relief.
Photo Credit: Boston Scientific
Source(s): Boston Scientific Corporation, Medical News Today